| scholarly article | Q13442814 |
| P50 | author | Dorothy Hatsukami | Q87445426 |
| P2093 | author name string | Stephen S Hecht | |
| Lois Biener | |||
| Irina Stepanov | |||
| Joni Jensen | |||
| Amy L Nyman | |||
| Robin Bliss | |||
| Aleksandar Knezevich | |||
| P2860 | cites work | Tobacco-specific nitrosamines in smokeless tobacco products marketed in India | Q46366479 |
| Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines | Q47978013 | ||
| Tobacco‐specific nitrosamines in new tobacco products | Q61207149 | ||
| Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff | Q69565971 | ||
| Prevalence of trial of snus products among adult smokers | Q83433812 | ||
| European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health | Q24678392 | ||
| New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. | Q33943746 | ||
| Test marketing of new smokeless tobacco products in four U.S. cities. | Q33988859 | ||
| Oral spit tobacco: addiction, prevention and treatment | Q34079745 | ||
| Oral Manifestations of Smokeless Tobacco Use | Q34150946 | ||
| The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. | Q34376467 | ||
| Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study | Q34627885 | ||
| Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study | Q34715402 | ||
| Oral tobacco products: preference and effects among smokers. | Q35189459 | ||
| Pharmacokinetics and pharmacodynamics of moist snuff in humans | Q35565115 | ||
| Smokeless tobacco use: harm reduction or induction approach? | Q35650428 | ||
| Receptivity to Taboka and Camel Snus in a U.S. test market | Q37353357 | ||
| Epidemiological evidence for the role of nitroso compounds in human cancer. | Q38769491 | ||
| Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. | Q39641695 | ||
| Nitrosamines and human cancer: introduction and overview | Q41277698 | ||
| Environmental exposure to N-nitroso compounds (NNOC) and precursors: an overview. | Q41277709 | ||
| Chemical composition and carcinogenicity of smokeless tobacco | Q41730562 | ||
| Smokeless tobacco: an addicting drug. | Q41730566 | ||
| Surveillance of smokeless tobacco nicotine, pH, moisture, and unprotonated nicotine content | Q44688196 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Camelus | Q7375 |
| nicotine | Q12144 | ||
| P304 | page(s) | 274-281 | |
| P577 | publication date | 2011-10-29 | |
| P1433 | published in | Nicotine and Tobacco Research | Q15762854 |
| P1476 | title | Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: findings from Round 1 of the New Product Watch | |
| P478 | volume | 14 |
| Q37151645 | (S)-N'-Nitrosonornicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats |
| Q39756867 | A Survey of N'-Nitrosonornicotine (NNN) and Total Water Content in Select Smokeless Tobacco Products Purchased in the United States in 2015. |
| Q39567870 | A longitudinal, naturalistic study of U.S. smokers' trial and adoption of snus |
| Q37637592 | Brief, instructional smokeless tobacco use among cigarette smokers who do not intend to quit: a pilot randomized clinical trial |
| Q46907405 | Characteristics of "American snus" and Swedish snus products for sale in Massachusetts, USA. |
| Q46734694 | Comprehensive chemical characterization of Rapé tobacco products: Nicotine, un-ionized nicotine, tobacco-specific N'-nitrosamines, polycyclic aromatic hydrocarbons, and flavor constituents. |
| Q45070774 | Consortium on Methods Evaluating Tobacco: Research Tools to Inform FDA Regulation of Snus. |
| Q34987618 | Evidence supporting product standards for carcinogens in smokeless tobacco products |
| Q37499926 | Exposure and Metabolic Activation Biomarkers of Carcinogenic Tobacco-Specific Nitrosamines. |
| Q90030118 | Exposure to a Tobacco-Specific Carcinogen Among Adolescent Smokeless Tobacco Users in Rural California, United States |
| Q33781291 | First-year college students' interest in trying dissolvable tobacco products. |
| Q57096122 | HRMAS NMR spectroscopy combined with chemometrics as an alternative analytical tool to control cigarette authenticity |
| Q28831487 | High levels of tobacco-specific N-nitrosamines and nicotine in Chaini Khaini, a product marketed as snus |
| Q43940036 | Impact of promotions on awareness, trial, and likelihood of trial of new dissolvable tobacco |
| Q36929832 | Levels of (S)-N'-nitrosonornicotine in U.S. tobacco products. |
| Q33949778 | Monitoring tobacco-specific N-nitrosamines and nicotine in novel smokeless tobacco products: findings from round II of the new product watch |
| Q45044780 | Naturalistic assessment of demand for cigarettes, snus, and nicotine gum. |
| Q31025978 | Nicotine and Toxicant Exposure among U.S. Smokeless Tobacco Users: Results from 1999 to 2012 National Health and Nutrition Examination Survey Data |
| Q37550741 | Nicotine delivery and pharmacologic response from Verve, an oral nicotine delivery product |
| Q33990091 | Public education about the relative harm of tobacco products: an intervention for tobacco control professionals |
| Q64121685 | Regulation of toxic contents of smokeless tobacco products |
| Q47436341 | Snus undermines quit attempts but not abstinence: a randomised clinical trial among US smokers |
| Q34518686 | The changing tobacco landscape: What dental professionals need to know |
| Q40088799 | Transcriptome profiling in oral cavity and esophagus tissues from (S)-N'-nitrosonornicotine-treated rats reveals candidate genes involved in human oral cavity and esophageal carcinogenesis. |
Search more.